Id: | acc4623 |
Group: | 1sens |
Protein: | AMPK |
Gene Symbol: | PRKAA1 |
Protein Id: | Q13131 |
Protein Name: | AAPK1_HUMAN |
PTM: | phosphorylation |
Site: | Thr183 |
Site Sequence: | MMSDGEFLRTSCGSPNYAAPE |
Disease Category: | Endocrine and metabolic diseases |
Disease: | Hepatic Steatosis |
Disease Subtype: | |
Disease Cellline: | HepG2 |
Disease Info: | |
Drug: | PCW |
Drug Info: | PCW is a drug. It may have specific pharmacological effects and uses in medical practice. |
Effect: | modulate |
Effect Info: | "The three main components in PCW, Poricoic acid, Pachymic acid, and Ergosterol, in cell experiments → ↑ phosphorylation of AMPK, ↑ phosphorylation of ACC, ↑ phosphorylation of SREBP1c, ↓ phosphorylation of mTOR, ↓ phosphorylation of P70S6K → Alleviate hepatic steatosis." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 31569635 |
Sentence Index: | 31569635_10 |
Sentence: | "Three compounds present in PCW including poricoic acid, pachymic acid, and ergosterol, significantly decreased FFA-induced increase in intracellular TG levels, consistent with increased AMPK phosphorylation, suggesting that poricoic acid, pachymic acid, and ergosterol are responsible for PCW-mediated amelioration of hepatic steatosis." |
Sequence & Structure:
MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEMCANLIKILAQ
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 3 | - | cardiovascular disease | ATC |
PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 1 | Completed | chronic lymphocytic leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACPRKAA1-Thr183 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.707 |
HGSC | -0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 183 | D | Colon cancer/carcinoma | Phosphorylation | 25679763 |
T | 183 | U | Breast cancer | Phosphorylation | 30413706 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.